Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 1

DB-08

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

  • NCT04556773 ↗
  • Active not recruiting
  • AstraZeneca
  • 22 commentary sources found
  • Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
YouTube10
X threads8
Podcasts4

The trial

ClinicalTrials.gov
Official title
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Phase
Phase 1
Status
Active not recruiting
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan; Durvalumab; Paclitaxel; Capivasertib; Anastrozole; Fulvestrant; Capecitabine
Arms
  • Module 1: T-DXd + capecitabine · Experimental
  • Module 2: T-DXd + durvalumab + paclitaxel · Experimental
  • Module 3: T-DXd + capivasertib · Experimental
  • Module 4: T-DXd + anastrozole · Experimental
  • Module 5: T-DXd + fulvestrant · Experimental
Enrollment
138
Primary outcomes
  • Occurrence of adverse events (AEs)- Part 1
  • Occurrence of serious adverse events (SAEs)- Part 1
  • Occurrence of adverse events (AEs)- Part 2
  • Occurrence of serious adverse events (SAEs)- Part 2
Sponsor
AstraZeneca with Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
Start
Dec 17, 2020
Primary completion
Aug 16, 2023
Results posted
No
Registry record
NCT04556773 · updated Aug 3, 2026